Actively Recruiting
Identifying Biomarkers in Alzheimer's Disease
Led by Chinese University of Hong Kong · Updated on 2022-12-19
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Alzheimer's disease (AD) is a serious brain disorder marked by gradual memory loss and declining thinking skills. It affects millions worldwide and is expected to increase significantly. Since AD currently has no prevention or cure, early detection is vital. Researchers aim to find biomarkers to improve early diagnosis and better understand the stages of AD, focusing on a local Chinese population in this observational study. Participants in this study will undergo various tests at the start, including cognitive assessments, blood tests, brain MRI and PET scans, and retinal imaging. There are four groups based on cognitive status, ranging from normal cognition to moderate or severe impairment. Follow-ups occur yearly for six years, with cognitive assessments each year and additional retinal imaging at the sixth year. During the study, participants will complete cognitive tests repeatedly, and researchers will measure brain changes using imaging and blood markers. They will track changes in memory and thinking skills over time using tests like the Hong Kong List Learn Test and Clinical Dementia Rating. Safety and health will be monitored throughout the six-year period, helping to evaluate the potential of these biomarkers in identifying and staging Alzheimer's disease early.
CONDITIONS
Brief Title
Identifying Biomarkers in Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chinese ethnicity
- For dementia group, clinical diagnosis of "probable Alzheimer's disease" according to recommendation from the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA)
You will not qualify if you...
- Clinical diagnosis of non-AD dementia
- Contraindication for MRI or PET
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
At baseline, participants undergo cognitive assessments, blood taking, Brain MRI scan, Brain PET scan and retinal imaging to identify biomarkers in Alzheimer's Disease.
1 baseline visit (in-person)
Duration - 6 years
Participants are followed yearly with cognitive assessments for the first five years and with cognitive assessment plus automatic retinal imaging at the sixth yearly follow-up to monitor changes over time.
6 yearly visits (in-person)
Trial Site Locations
Total: 1 location
1
Chinese University of Hong Kong
Hong Kong, Hong Hong, Hong Kong
Actively Recruiting
Research Team
P
Pualine Kwan
E
Elyia Han
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here